PROCalcitonin-based algorithm for antibiotic use in Acute Pancreatitis (PROCAP): study protocol for a randomised controlled trial.

Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215 (Electronic) Linking ISSN: 17456215 NLM ISO Abbreviation: Trials Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2006-

Algorithms* ; Decision Support Techniques*; Anti-Bacterial Agents/*therapeutic use ; Drug Monitoring/*methods ; Pancreatitis/*drug therapy ; Procalcitonin/*blood; Anti-Bacterial Agents/adverse effects ; Anti-Bacterial Agents/economics ; Biomarkers/blood ; Clinical Decision-Making ; Clinical Trials, Phase III as Topic ; Cost Savings ; Cost-Benefit Analysis ; Drug Costs ; Drug Monitoring/economics ; England ; Humans ; Pancreatitis/blood ; Pancreatitis/diagnosis ; Pancreatitis/economics ; Pragmatic Clinical Trials as Topic ; Predictive Value of Tests ; Single-Blind Method ; Time Factors ; Treatment Outcome

Background: Differentiating infection from inflammation in acute pancreatitis is difficult, leading to overuse of antibiotics. Procalcitonin (PCT) measurement is a means of distinguishing infection from inflammation as levels rise rapidly in response to a pro-inflammatory stimulus of bacterial origin and normally fall after successful treatment. Algorithms based on PCT measurement can differentiate bacterial sepsis from a systemic inflammatory response. The PROCalcitonin-based algorithm for antibiotic use in Acute Pancreatitis (PROCAP) trial tests the hypothesis that a PCT-based algorithm to guide initiation, continuation and discontinuation of antibiotics will lead to reduced antibiotic use in patients with acute pancreatitis and without an adverse effect on outcome.
Methods: This is a single-centre, randomised, controlled, single-blind, two-arm pragmatic clinical and cost-effectiveness trial. Patients with a clinical diagnosis of acute pancreatitis will be allocated on a 1:1 basis to intervention or standard care. Intervention will involve the use of a PCT-based algorithm to guide antibiotic use. The primary outcome measure will be the binary outcome of antibiotic use during index admission. Secondary outcome measures include: safety non-inferiority endpoint all-cause mortality; days of antibiotic use; clinical infections; new isolates of multiresistant bacteria; duration of inpatient stay; episode-related mortality and cause; quality of life (EuroQol EQ-5D); and cost analysis. A 20% absolute change in antibiotic use would be a clinically important difference. A study with 80% power and 5% significance (two-sided) would require 97 patients in each arm (194 patients in total): the study will aim to recruit 200 patients. Analysis will follow intention-to-treat principles.
Discussion: When complete, PROCAP will be the largest randomised trial of the use of a PCT algorithm to guide initiation, continuation and cessation of antibiotics in acute pancreatitis. PROCAP is the only randomised trial to date to compare standard care of acute pancreatitis as defined by the International Association of Pancreatology/American Pancreatic Association guidelines to patients having standard care but with all antibiotic prescribing decisions based on PCT measurement.
Trial Registration: International Standard Randomised Controlled Trial Number, ISRCTN50584992. Registered on 7 February 2018.

N Engl J Med. 2009 Jan 29;360(5):439-43. (PMID: 19179312)
Gut. 2013 Jan;62(1):102-11. (PMID: 23100216)
JOP. 2013 May 10;14(3):221-7. (PMID: 23669469)
Scand J Gastroenterol. 2011 Nov;46(11):1389-98. (PMID: 21830851)
Lancet. 2005 Feb 19-25;365(9460):711-22. (PMID: 15721478)
Lancet Infect Dis. 2016 Jul;16(7):819-827. (PMID: 26947523)
Scand J Gastroenterol. 2011 Mar;46(3):261-70. (PMID: 21067283)
Br J Clin Pharmacol. 2001 Jun;51(6):523-9. (PMID: 11422011)
J Hepatobiliary Pancreat Sci. 2015 Apr;22(4):316-21. (PMID: 25678060)
Am J Gastroenterol. 2013 Sep;108(9):1400-15; 1416. (PMID: 23896955)
Scand J Gastroenterol. 2012 Sep;47(8-9):1064-70. (PMID: 22631566)
Surgery. 2009 Jul;146(1):72-81. (PMID: 19541012)
Arch Intern Med. 2011 Aug 8;171(15):1322-31. (PMID: 21824946)
Lancet. 2010 Feb 6;375(9713):463-74. (PMID: 20097417)
Lancet. 2000 Oct 7;356(9237):1255-9. (PMID: 11072960)
J Hepatobiliary Pancreat Sci. 2011 Sep;18(5):678-83. (PMID: 21431888)
Cochrane Database Syst Rev. 2010 May 12;(5):CD002941. (PMID: 20464721)
Br Med Bull. 2010;96:5-21. (PMID: 21037243)
HPB (Oxford). 2009 Aug;11(5):391-7. (PMID: 19768143)
Ann R Coll Surg Engl. 2002 Mar;84(2):79-81. (PMID: 11995768)
Indian J Gastroenterol. 2014 Sep;33(5):458-65. (PMID: 25138788)
Lancet. 2017 Aug 26;390(10097):826-829. (PMID: 28711319)
Ann Surg. 2007 May;245(5):745-54. (PMID: 17457167)
Saudi Med J. 2012 Apr;33(4):382-7. (PMID: 22485232)
HPB (Oxford). 2013 Oct;15(10):822-7. (PMID: 24028271)
Pancreatology. 2016 Nov - Dec;16(6):946-951. (PMID: 27613614)
BMJ. 2004 Jun 19;328(7454):1466-9. (PMID: 15205290)
Pancreatology. 2013 Jul-Aug;13(4 Suppl 2):e1-15. (PMID: 24054878)
Health Technol Assess. 2015 Nov;19(96):v-xxv, 1-236. (PMID: 26569153)

Keywords: Acute pancreatitis; Antibiotics; Procalcitonin

0 (Anti-Bacterial Agents)
0 (Biomarkers)
0 (Procalcitonin)

Date Created: 20190731 Date Completed: 20200129 Latest Revision: 20240718

20240718

PMC6664733

10.1186/s13063-019-3549-3

31358032